ArticleDrug metabolism and disposition: the biological fate of chemicals2025
An in vitro evaluation of common botanical extracts on carboxylesterase 1 catalytic activity.
Article in Drug metabolism and disposition: the biological fate of chemicals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Carboxylesterase 1 (CES1) is an abundant hepatic drug metabolizing enzyme whose substrates include endogenous compounds and medications from a variety of therapeutic classes. CES1 is a serine hydrolase that catalyzes the cleavage of amides, esters, and thioesters. Concerns have been raised over botanical-drug interactions (BDIs) and their potential to impair enzymatic function resulting in therapeutic failures or adverse effects. BDIs have been extensively investigated with the cytochrome P450 family of enzymes; however, CES1 BDIs have remained largely uninvestigated. This study assessed the CES1 in vitro inhibitory effects of 18 commonly used botanical extracts and their major constituents using an established probe assay and liquid chromatography-tandem mass spectrometry analysis. The following plant extracts demonstrated significant reversible inhibition of CES1 metabolism: ashwagandha, cannabis, saw palmetto, St. John's wort, turmeric, and yohimbe. The following phytochemical constituents demonstrated significant reversible inhibition of CES1: cannabigerol, curcumin, lauric acid, linoleic acid, hypericin, hyperforin, kaempferol, and tetrahydrocannabinolic acid. Tetrahydrocannabinolic acid was the most potent inhibitor of CES1 and displayed a complete mixed competitive-noncompetitive type inhibition. Cannabis, St. John's wort, and turmeric all displayed inhibition potencies (inhibition constants; K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.